Funding
← Back to your selection

Taiho Ventures

Activity from announced rounds

All recorded activity
Rounds participated in
3
Confirmed lead rounds
—
3 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$197.1M
3 disclosed · full round size, not this investor’s share

By stage

Series B2
Seed1

By primary sector

Biotech3

By country

United States2
France1

Rounds

3 in all activity
Signadori Bio

Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage

Role not disclosed
EpiBiologics

Develops bispecific antibodies for targeted degradation of extracellular proteins.

$107MSeries B
Role not disclosed